# Study Of Safety, Tolerability And Pharmacokinetics Of Subcutaneous Doses Of TA-46

> **NCT04410809** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 78 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** TA-46
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04410809
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-19
- **Primary completion:** 2019-11-27
- **Final completion:** 2019-11-27
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2020-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04410809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04410809, "Study Of Safety, Tolerability And Pharmacokinetics Of Subcutaneous Doses Of TA-46". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04410809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*